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SUMMARY
We estimated prevalence and incidence of liver condition outcomes, and costs to the health
service of diagnosed hepatitis B virus (HBV) in Tayside, UK. HBV patients were identiﬁed from
electronic virology data between 1989 and 2003. The health resource costs of HBV for surface
antigen-positive (HBsAg+) patients and HBV (HBsAg+ or immune, i.e. recovered) patients
were calculated. A total of 633 patients had HBV (275 HBsAg+), and were more likely to
be male (62% vs. 48%), older (mean age 42.6 vs. 39.2 years) and deprived than the general
population. The prevalence of immune individuals increased steadily. Post-HBV diagnosis, 24%
of immune and 13% of HBsAg+ patients were diagnosed with a liver condition. The median
cost per immune patient (£3023) was greater than per HBsAg+ patient (£1498) (P=0.02). While
increasing prevalence of immune HBV patients highlights an increase in screening and treatment,
the costs associated with this group are high.
Key word : Hepatitis B.
INTRODUCTION
Hepatitis B virus (HBV) infection has a high pre-
valence worldwide. The World Health Organization
estimated that about 2 billion people have been in-
fected, and 350 million live with chronic infection [1].
The virus is responsible for 500 000 to 1.2 million
deaths per year [2]. Globally, 30% of cirrhosis and
78% of hepatocellular carcinoma (HCC) are attribu-
table to HBV [3]. In Europe, it is estimated that 1
million people are exposed annually to HBV, with
22 000 dying from cirrhosis and liver cancer due to the
infection [4]. In the UK, a report by the Hepatitis B
Foundation UK estimated that chronic hepatitis B
infection almost doubled from 180000 in 2002 to
320 000 in 2007 [5].
Due to the high morbidity and mortality associated
with liver disease and HCC, the economic burden of
HBV is considerable [2], with healthcare costs esti-
mated at over three times higher for chronic hepatitis
B than controls [6]. Ascertainment of the true inci-
dence of liver diseases such as HBV is a diﬃcult but
crucial task that is required to adequately identify re-
search needs and assess health resource implications.
This population-based retrospective cohort study
aimed to estimate the crude prevalence and incidence
rates of diagnosed HBV in Tayside, UK, describe the
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liver condition outcomes between patients with dif-
ferent stages of HBV, and estimate the hospitalization
costs associated with HBV-infected patients.
MATERIALS AND METHODS
Study population
This study was carried out on people who were
residents of Tayside, Scotland in the study period
1989–2003. Tayside is a mixed urban/rural region in
the eastern side of the central belt of Scotland. It is
representative of Scotland with regards to age, gen-
der, ethnicity and unemployment, and has a popu-
lation of approximately 429 000 [7]. All patients who
were ever diagnosed with HBV during the study per-
iod were identiﬁed from the virology dataset from
Ninewells Hospital where all viral hepatitis tests in the
Tayside region are performed, thus giving complete
population coverage. Requests for viral hepatitis tests
were from general practice (primary care), hospital
(general admissions and specialist clinics) and
institutional services (e.g. prison service).
Patient data were extracted and anonymized by the
Health Informatics Centre (HIC) [8]. The databases
relevant to this study, listed below, covered the entire
study period and were used within procedures
approved under the Data Protection Act and
Caldicott Guardian with annual external audit.
(1) Virology database. Computerized patient-speciﬁc
records exist for all requests for viral serology
from primary and secondary care for hepatitis
viruses for the Tayside region and all tests were
extracted from the period 1989 to 2003.
(2) Scottish Morbidity Records (SMR01). This is a
list of hospital admissions for all hospitals in
Scotland. Type and dates of hospital admissions
for viral hepatitis subjects were obtained from this
data setfor Tayside.
(3) Epidemiology of Liver Disease In Tayside
(ELDIT). Contains all Tayside patients with liver
diseases that have been ‘electronically ’ diagnosed
using record-linkage of biomedical datasets, in-
cluding virology and immunology [9]. The data-
base has been used for research projects such as
the ALFIE study [10]. ELDIT was used to ident-
ify liver disease outcomes in HBV patients.
(4) Carstairs social deprivation categories. The Car-
stairs score is a socioeconomic measure based on
data derived from the decennial census and linked
to all residents in Tayside, via the postcode [11].
The score is divided into seven categories in order
of deprivation where one is most aﬄuent and
seven is the most deprived.
All of the electronic databases described above were
electronically linked using a unique identiﬁer, the
community health index (CHI) [12]. In Scotland, the
CHI is assigned to every patient registered with a
general practice and is contained within all of the
databases described above. The CHI is a 10-digit
number where the ﬁrst six digits are the patient’s data
of birth, the seventh and eighth digits are a marker for
gender, and the last two digits are check digits. Since
the CHI contains person identiﬁable information, the
data protection oﬃcer at HIC mapped it to a project
speciﬁc anonymous ten-digit code and removed the
CHI.
An algorithm was used to assign disease states. For
most of the study period, HBV DNA was not avail-
able, so disease states are based on virological para-
meters extracted from the virology database. The
algorithm, based on these limitations, assigned a
patient’s HBV as: acute if the surface antigen of the
HBV (HBsAg) is positive (+) and the hepatitis B
core antibody immunoglobulin M (HBcAbIgM)+
(at high titre, i.e. o50 IU/l) ; chronic active infection
if HBsAg+, hepatitis B ‘e’ antigen (HBeAg)+ and
HBcAbIgM negative (low titre <50 IU/l) ; low infec-
tivity carrier if HBsAg+ and hepatitis B ‘e ’ antibody
(HBeAb)+ ; and immune (i.e. recovered) if hepatitis B
surface antibody (HBsAb)+ and hepatitis B core
antibody (HBcAb)+. This system means that some
patients who are pre-core mutants will be included in
the carrier group, but without the wider availability of
HBV DNA in the earlier patients in the cohort this is
unavoidable. The ﬁrst date of each stage was used as
date of diagnosis.
Cost analysis
The cost of hospitalization for viral hepatitis patients
was calculated with 2009 net costs by speciality group
for Ninewells Hospital, obtained from the Scottish
Health Services Cost book on the Information
Statistics Division website [13]. Although our study
period ended in 2003, we used 2009 costs to reﬂect the
current economic climate. The direct medical costs for
hospitalized patients included hospital charges to
house the patient in the hospital per day, laboratory
testing, physician’s fees, allied health professional
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staﬀ and diagnostic procedures, but excluded both
liver-speciﬁc and non-liver-speciﬁc medication costs.
If a speciﬁc speciality group was not available at
Ninewells Hospital, the average cost for all Scottish
hospitals which did have the speciality was used. The
median costs of hospitalization for immune patients
and HBsAg+ patients were compared using the
Mann–Whitney test. The proportion of costs related
to admission for liver disease was calculated.
Liver disease admissions were identiﬁed from
the International Classiﬁcation of Diseases codes
(versions 9 and 10) in the SMR01 database.
Statistical analysis
Crude estimates of yearly incidence and prevalence
rates were based on the number of Tayside residents
with newly diagnosed viral hepatitis B in each year
from 1989 by stage and on those whose stage of
hepatitis B changed during the study period. In cal-
culating these estimated rates, the entire population of
Tayside for the year was considered to be at risk. The
denominator was estimated from the yearly General
Register Oﬃce for Scotland population estimates.
The rates from 1989 to 1998 have been reported in a
previous study [14]. A dynamic population was used
from 1989 to 2003 to account for migration. For the
description of liver condition outcomes and cost
analysis, a more ﬁxed population was used where only
patients who had always lived in Tayside from 1989 to
2003 or who moved into Tayside and remained there
until the end of the study were included. This was
because there was no way of knowing the exact date a
patient left Tayside.
Kaplan–Meier curveswere used to illustrate the time
to liver condition diagnosis in hepatitis B patients for
immune patients and carriers from the incident date
of positive sample. Acute infected patients were not
included because in reality these patients do not stay
in this stage long and so there will be too few patients
(and hence events) in these groups. However, they
were included in the descriptive table of liver con-
dition outcomes. Statistical analyses were performed
using SAS version 9.3 (SAS Institute Inc., USA).
RESULTS
Among Tayside residents a total of 633 patients were
identiﬁed with viral hepatitis B in the study period
1989-2003. Of these, 275 (43%) patients were ident-
iﬁed as HBsAg+ or having once been HBsAg+, and
400 (63%) were immune. Of the 633 patients, 42 sero-
converted from HBsAg+ to HBsAb+ (i.e. immune)
during observation, so 358 patients had previous
infection but were immune either at point of testing
for HBV or at ﬁrst entry into the electronic database.
Of the HBsAg+ patients, 78 had acute infection. Of
these, 47 had a diﬀerent ﬁnal recorded stage of HBV
(30 immune, seven carrier, 10 chronic active). Of the
HBsAg+ patients, 48 had chronic active infection, of
whom six became carriers and seven became immune.
The descriptive analyses of the patients are given in
Table 1. HBV patients were slightly older than the
general population average and tended to live in less
aﬄuent areas. However, the mean age of chronic
active patients was 5.6 years younger than the
population average. HBV patients were more likely to
be male compared to the general population.
The estimated incidence and prevalence of diag-
nosed viral hepatitis B infection by stage are displayed
in Figure 1(a, b), respectively. Only estimated inci-
dence is given for the diagnosed acute stage as this
lasts for 6 months by deﬁnition. The estimated
prevalence of diagnosed chronic active hepatitis B
increased steadily each year until 1996, and then re-
mained reasonably steady at around 4/100 000 until
2003. The estimated prevalence of diagnosed hepatitis
B carriers increased steadily until 1999 and remained
reasonably constant between 26 and 28/100 000 until
2003. The overall estimated prevalence of diagnosed
HBsAg+ rose to 37/100 000 in 1999 and stayed fairly
steady. The estimated prevalence of diagnosed
immune patients increased at a steady rate each year
to 60/100 000 in 2003.
Liver condition diagnosis
Out of the 334 immune patients who were in the ﬁxed
Tayside population, 40 had a liver condition before
their ﬁrst recorded HBV test. Of these, 22 had HCV
and 13 had alcohol-related liver disease. Post-HBV
diagnosis, one quarter (n=80) of the immune patients
had a liver condition diagnosed (of whom only six had
a diagnosis of a diﬀerent liver condition before their
ﬁrst recorded HBV test) (see Table 2). From Figure 2
it is clear that the majority of liver conditions were
diagnosed on the same day as the ﬁrst HBV test. HCV
was the most frequently diagnosed liver condition,
infecting 64 (19%) immune patients (including HCV
in combination with other conditions). Only 10%
of all diagnosed HBV carriers were later diagnosed
with a liver condition. Four out of 22 patients were
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diagnosed with a liver condition while in the acute
stage and 6/22 while in the chronic active stage.
Cost analysis
Table 3 shows the frequency of hospital admission,
length of stay and cost analysis for HBV patients, and
separately for HBsAg+ and immune patients. The
median cost per HBV patient admitted was £8453 and
per HBV patient was £2394. The median cost per
patient admitted (P=0.02) and the median cost per
patient (P=0.02) were both signiﬁcantly greater for
immune patients than HBsAg+ patients. However,
there was no signiﬁcant diﬀerence in the median
length of stay between the two groups, which was 4
days. The proportion of the total hospitalization costs
that were related to admissions for liver disease was
17.1% (£1 108 078 out of £6 480 828). For HBsAg+
patients the proportion was 27.6% (£374 209 out of
£1 354 865) and for immune patients the proportion
was 14.3% (£733 870 out of £5 125 442).
DISCUSSION
This study found that the prevalence of HBsAg+ (i.e.
acute, carrier, chronic) remained reasonably constant
between 34 and 37 cases/100 000 person-years from
1999 to 2003. The prevalence of immune patients rose
steadily each year. Twelve percent of immune patients
were diagnosed with a liver condition before their ﬁrst
recorded HBV test and a further 22% were diagnosed
post-test. Of those diagnosed post-HBV test, 80%
were diagnosed with HCV. The median direct hospi-
tal costs per HBV immune patient were more than
double the median costs per HBsAg+ patient. Over a
quarter of the costs for HBsAg+ patients were re-
lated to admissions with liver disease compared to
only 14% for immune patients.
However, these results should be interpreted in
light of the underlying denominator of people tested
for HBV in Tayside. The samples originated from all
clinical services across Tayside, with the majority
from hospital-based practice. While we do not have
indications for testing in our database, we can specu-
late that the main reasons for testing include the
presence of symptoms of acute hepatitis or chronic
liver disease, being part of a broader work-up for
other conditions and screening. The ﬁrst two reasons
most probably relate to those patients with acute or
chronic active infection, while the latter is the most
likely reason for testing in the immune group, due toT
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these patients having a range of factors that are likely
to increase the risk of a liver condition, e.g. injecting
drug use. Those screened may also include pregnant
women undergoing antenatal screening, which was
introduced in Tayside in the early 1990s. Therefore it
is important to note that the results found in patients
tested for HBV may not be representative of the total
population of patients who have HBV.
Strengths and limitations
Tayside is a mixed rural urban health board with
varied socioeconomic status. The population in
Tayside is predominantly caucasian with less than 2%
immigrants [7]. Our electronic databases did not
contain information on indications for testing or
ethnic origin of HBV patients which could be major
confounders for the disease. However, since im-
migrants from high-prevalence countries are a high-
risk group for HBV, we can assume that a higher
proportion of immigrants make up the HBV popu-
lation than the general population of Tayside. Since
the percentage of immigrants in Tayside is similar to
the whole of Scotland, our ﬁndings may be regarded
as the background rate of diagnosed HBV infection
and cost for Scotland. Clearly there will be other
localities throughout the UK with higher rates of
chronic HBV due to immigrants from endemic areas.
The study period ended in 2003 which may impact
the relevance of the ﬁndings to the present with regard
to changes in healthcare, treatment and immigration.
Estimates of net migration in Tayside and throughout
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Fig. 1. (a) Estimated incidence and (b) prevalence of diagnosed hepatitis B in Tayside by stage of disease over 14 years.
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Table 2. Liver conditions diagnosed post-HBV diagnosis by HBV stage
Liver condition
Stage of hepatitis B virus
Acute (N=22)
n (%)
Chronic active
(N=22) n (%)
Carrier
(N=122) n (%)
Immune (N=334)
n (%)
All (N=500)
n (%)
HCV only 2 (9) 1 (5) 4 (3) 56 (17) 63 (13)
Cirrhosis only 1 (5) 2 (9) 3 (2) 4 (1.2) 10 (2)
HCC only 1 (5) 1 (5) 1 (1) 1 (0.3) 4 (0.8)
ARLD only 0 1 (5) 0 2 (0.6) 3 (0.6)
HCV+ARLD 0 1 (5) 0 2 (0.6) 3 (0.6)
HCV+cirrhosis+ARLD 0 0 1 (1) 2 (0.6) 3 (0.6)
Alcoholic hepatitis only 0 0 0 2 (0.6) 2 (0.4)
Hepatitis A virus only 0 0 0 2 (0.6) 2 (0.4)
HCV+cirrhosis 0 0 1 (1) 1 (0.3) 2 (0.4)
HCV+cirrhosis+HCC 0 0 0 2 (0.6) 2 (0.4)
Cirrhosis+HCC 0 0 0 2 (0.6) 2 (0.4)
ARLD+cirrhosis 0 0 0 2 (0.6) 2 (0.4)
Autoimmune hepatitis only 0 0 0 1 (0.3) 1 (0.2)
Fatty liver disease only 0 0 1 (1) 0 1 (0.2)
ARLD+HCC+cirrhosis 0 0 1 (1) 0 1 (0.2)
HCV+alcoholic hepatitis 0 0 0 1 (0.3) 1 (0.2)
Any 4 (18) 6 (27) 12 (10) 80 (24) 102 (20)
Time to diagnosis, median (IQR), days 5 (0–46.5) 37.5 (0–133) 47 (0–832) 0 (0–29.5) 0 (0–71)
HCV, Hepatitis C virus ; HCC, hepatocellular carcinoma; ARLD, alcohol-related liver disease ; IQR, interquartile range.
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Scotland have increased yearly suggesting that the
incidence and prevalence of carriers may have in-
creased at a greater rate during the past 8 years [14].
With the advancement of HBV treatment and im-
provements in healthcare the lengths of stay in
hospital may be shorter. However, with the increase
in treatment and healthcare costs we would expect
changes in the median cost per patient to be minimal.
It is important to note that prevalence estimates of the
diagnosis of HBV stage are strictly from 1989. We
have no records of the ‘base’ prevalence before this
period. The true incidence and prevalence of HBV
diagnosis (regardless of stage) throughout the study
period may well be slightly higher than estimated here
since there may be a small percentage of error in
Tayside residency data or laboratory data entry.
Obviously, we would expect the true incidence and
prevalence of HBV to be higher than our estimates
since many individuals with acute infection are never
tested, particularly asymptomatic patients.
This study extends previous work published on the
prevalence and economic burden of hepatitis B on an
earlier dataset [15], and, to our knowledge, remains
the ﬁrst population-based study that has record-
linked clinical data to identify viral hepatitis subjects
from primary and secondary care. These results are
derived from unselected ‘real-world’ observations in
a geographically deﬁned population. The database
created for this study forms part of the ELDIT
database [9]. ELDIT was created via the record-
linkage of various datasets including SMR01 hospital
admissions, the SMR06 cancer registry, and hospital
datasets containing virology, immunology, patho-
logy, and endoscopy information. Each liver disease
was electronically diagnosed using strict algorithms.
Uniquely, in Tayside, record-linkage using the CHI
number allows investigation of the whole area popu-
lation to measure incidence and prevalence of diag-
nosed disease rather than depending on referral
patterns with multiple in-built biases and faults.
A limitation of the study was the lack of an exact
emigration date from Tayside for the whole study
period meaning that censoring due to migration could
not be accounted for in our survival and hospital ad-
missions analyses. Only the year of emigration from
Tayside was known. Therefore, only patients who re-
sided in Tayside from their ﬁrst recorded HBV test
until the end of 2003 were included. Comparing the
denominators in Tables 1 and 3 we observed that 66/
400 (16.5%) immune patients and 109/275 (39.6%)
HBsAg+ patients left Tayside before the end of the
period. The larger proportion for the latter group is
not surprising given that HBV carriers are pre-
dominantly immigrants who tend to change location
more regularly than natives, who comprise the ma-
jority of the immune group. Another limitation is that
the cost analysis only included direct medical costs
and excluded both liver-speciﬁc and non-liver-speciﬁc
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Fig. 2. Kaplan–Meier plot of time to liver disease diagnosis from ﬁrst hepatitis B test for HBV chronic active infected
patients, carriers and immune patients.
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medication costs. The cost of medication for a HBV
patient varies from £1095 to £8424 per annum de-
pending on disease severity and type of drug used [16].
The classiﬁcation of patients was based only on
HBV antibody and antigen status, but this is unlikely
to have impacted on the prevalence and incidence
estimates of diagnosis. The reason for this older
classiﬁcation is of course due to the long duration of
this study during which time HBV DNA measure-
ment was not routinely available. It does mean that
some patients who were pre-core mutants, who
should ideally have been quantiﬁed as a separate
group, have been classiﬁed as ‘carriers ’.
Diagnosis of liver condition
The study produced the very interesting observation
that HBV carriers had a lower rate of diagnosis of a
liver condition than immune patients and as a con-
sequence immune patients cost the health service
more than those chronically infected with HBV,
which is counter-intuitive. There are three possible
explanations for this, one with positive connotations
for the consequences of diagnosis and the other two
more pragmatic. First, a patient knowing that they
have chronic hepatitis may become more health aware
and reduce risk behaviours compared to those who
ﬁnd they are immune and have no need to change
behaviour. There is some evidence for such beha-
vioural change in hepatitis C patients [17]. The se-
cond, and perhaps more likely explanation, is that
carriers might be less likely to be injecting drug users
(IDUs) since IDUs acquire infection in adult life,
usually present acutely, and eventually clear the virus.
Hence, the lower rate of liver condition diagnosis in
carriers may be related to the lower incidence of the
many pathologies associated with IDUs, including
overdose, suicide, endocarditis, hepatitis C and HIV.
Third, healthy migrant selection may explain the
lower rate of diagnosis in carriers, since those with
a more aggressive form of HBV may be too unwell
to achieve the economic status required to permit
migration [18].
Hospital costs
The median cost per patient admitted for immune
patients was twice that for chronic active and carrier
patients. Again, this can be explained by the fact that
the latter group of patients are likely to have had
vertical infection and are predominantly immigrants,
whereas immune patients are likely to have been
Table 3. Hospital admission frequencies, length of stay and costs for HBsAg-positive patients, immune patients and
all HBV patients
Hospital admission variable HBsAg+ (N) Immune (N) HBV (N)
(A) Number of patients 166 334 500
(B) Number of patients admitted 102 222 324
(C) Number of admissions 300 1059 1359
(D) No hospital admission reported 64 112 176
Average number of hospital admissions (C/A) 1.8 3.2 2.7
Re-admissions to hospital per patient (C – B)/B 1.9 3.8 3.2
Length of stay (LOS)
Mean (¡S.D.) LOS per hospital stay (days) 8.33¡15.46 7.95¡18.30 8.03¡17.71
Median (range) (days) 4 (1–197) 4 (1–415) n.s. 4 (1–415)
(E) Total cost of admitted cases £1 354 865 £5 125 442 £6 480 828
Average cost per patient (E/A) £8162 £15 346 £12 962
Average cost per patient admitted (E/B) £13 283 £23 088 £20 003
Average cost per admission (E/C) £4516 £4840 £4769
Median cost per patient admitted £6377 £9326* £8453
Median cost per patient £1498 £3023* £2394
HBV, Hepatitis B virus ; HBsAg+, HBV surface antigen positive ; S.D., standard deviation.
Net costs were obtained from the Information Statistics Division website. Ninewells Hospital speciality group costs were used
where possible, otherwise the average cost for Scotland was used. Where a patient moved to a diﬀerent speciality during the
same stay the daily costs for each speciality were halved on the day of the move.
Mann–Whitney test for immune patients vs. HBsAg+ patients.
* P<0.05 ; n.s., not statistically signiﬁcant.
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infected in adulthood due to injecting drug use or
risky sexual behaviour. Therefore the higher cost for
immune patients is probably due to the conditions or
diseases that are connected to the behaviours of these
patients rather than HBV. For example, a total of 86
(25.7%) of the 334 immune patients had HCV (22
before their initial HBV test and 64 post-test) com-
pared to only seven (5.7%) of the 122 carriers (one
before their initial HBV test and six post-test).
However, it should be stressed that only 14.3% of the
hospitalization costs for immune patients were related
to liver disease admissions. It is unsurprising that the
proportion of costs attributable to liver disease in the
HBsAg+ group is higher than in the immune group
as the former have an active liver disease.
CONCLUSIONS
While the estimated incidence and prevalence of di-
agnosed HBV remained reasonably steady until 2003,
the recent increase of immigrants may result or may
have already resulted in an increase. The estimated
incidence and prevalence of diagnosed immune HBV
patients is steadily increasing. While this highlights an
increase in screening and treatment for the virus, the
costs associated with this group of patients are very
high even though we did not include medication costs.
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